Pomerantz is Co-Lead Counsel in a securities class action against AT&T, alleging that the company fabricated thousands of customer accounts at its DirecTV affiliate and then misled investors about the health of its flagship streaming product.

Read more here!

Pomerantz recently achieved a recovery of $110 million for the Class (pending court approval) in this high-profile class action against Fiat Chrysler, for misrepresentations about the company’s business practices that caused at least 3.1 million Chrysler cars and trucks to be unsafe to drive.

Read about the case here.

Pomerantz, as Lead Counsel, achieved a $27 million settlement for the Class in this high-profile litigation against Barclays. We alleged that, while Barclays stated that it monitored its "dark pool" to eliminate “toxic” trading, it actively encouraged predatory traders to engage in dark pool trading.

Read about the case here.

In a significant victory for investors, Pomerantz, as sole lead counsel for the class, along with Lead Plaintiff Universities Superannuation Scheme Limited, achieved a historic $3 billion partial settlement with Petroleo Brasileiro S.A.--Petrobras and its auditor, PwC Brazil.

View case details

In September 2018, Pomerantz, as co-lead counsel, achieved a settlement of $80 million in a securities class action against technology and media giant Yahoo over allegations related to two data breaches in 2014, in which over 1.5 billion Yahoo user accounts were compromised. This is the first significant settlement to date of a securities fraud class action filed in response to a data breach.

Read about the case here

Pomerantz leads a securities class action litigation against CVS, the nation’s largest pharmacy chain, for failing to disclose financial problems associated with its acquisition of Omnicare.

Read about the case here.

In December 2018, Pomerantz achieved a $31 million partial settlement with three defendants on behalf of a class of U.S. lending institutions that suffered losses arising out of the LIBOR rate-fixing scandal, which impacted trillions of dollars in investments.

Pomerantz survived defendants’ motion to dismiss this litigation against the high-profile pharmaceutical company for charges related to Mylan's alleged systemic practice of over-charging Medicaid for its Epi-pens.

Read about the case here.

In July 2018, the court denied in largest part the defendants’ motion to dismiss this important securities class action against international pharmaceutical company, Perrigo plc. Plaintiffs allege that the company misled investors as to its revenue growth potential in order to encourage them to reject a tender offer by Mylan N.V.

Read about the case here.

Pomerantz’s cutting-edge legal theory for investors who purchase securities on foreign exchanges is overcoming obstacles created by SCOTUS in Morrison.

Read more

Pomerantz represents Lead Plaintiff in a securities class action against Tesla, Inc. alleging that Tesla misled investors regarding production numbers for its Model 3 car. The FBI is reviewing those production numbers as part of an ongoing criminal probe into Tesla.

Pomerantz is co-lead counsel in a securities class action against holding company Blue Apron Holdings, Inc., which, through its subsidiaries, provides meal-kit delivery services. The action concerns allegations related to the company misleading investors as to its business, operational and compliance policies.

Read about the case here.

Pomerantz represents several institutional investors in an individual action against pharmaceutical giant Teva relating to alleged anticompetitive practices in Teva’s sales of generic drugs.

Read more here.